Citing migraine drug growth and pandemic, Lundbeck to cut 300 jobs and close India facility

The Danish biopharma Lundbeck has seen its fair share of R&D setbacks over the years but it’s taken pride in Vyepti, the CGRP migraine drug approved in February 2020. And according to Lundbeck execs, the drug is proving so successful it’s forcing layoffs in other parts of the company.


Click to view original post